ENTEROME

company

About

Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.

  • 51 - 100

Details

Last Funding Type
Series E
Last Funding Money Raised
€46.30M
Industries
Biopharma,Biotechnology,Health Care,Life Science
Founded date
Jan 1, 2012
Number Of Employee
51 - 100
Operating Status
Active

Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€46.30M
ENTEROME has raised a total of €46.30M in funding over 2 rounds. Their latest funding was raised on Jun 25, 2020 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 25, 2020 Series E €46.30M 1 Detail
Jan 4, 2018 Debt Financing 1 European Investment Bank Detail

Investors

Number of Lead Investors
Number of Investors
1
2
ENTEROME is funded by 2 investors. European Investment Bank and Takeda are the most recent investors.
Investor Name Lead Investor Funding Round
European Investment Bank Yes Debt Financing
Takeda Series E